{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:54:26Z","timestamp":1782219266804,"version":"3.54.5"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007401","name":"Sri Ramachandra University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12181-3","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:29:13Z","timestamp":1782217753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The functional dichotomy of exosomal microRNAs in TNBC: implications for chemoresistance and integrated theranostics"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3697-0917","authenticated-orcid":false,"given":"Afreen","family":"Aftab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-5806","authenticated-orcid":false,"given":"Sumathy","family":"Arockiasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Satish Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundersingh","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Pavithra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambalathandi","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"12181_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer. J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"J Clin"},{"key":"12181_CR2","volume-title":"Breast Cancer","author":"E Orrantia-Borunda","year":"2022","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE et al (2022) Subtypes of Breast Cancer. In: Mayrovitz HN (ed) Breast Cancer. Exon Publications, Brisbane (AU)"},{"key":"12181_CR3","doi-asserted-by":"publisher","first-page":"720076","DOI":"10.3389\/fphar.2022.720076","volume":"13","author":"H Kumar","year":"2022","unstructured":"Kumar H, Kumar RM, Bhattacharjee D et al (2022) Role of Nrf2 Signaling Cascade in Breast Cancer: Strategies and Treatment. Front Pharmacol 13:720076. https:\/\/doi.org\/10.3389\/fphar.2022.720076","journal-title":"Front Pharmacol"},{"key":"12181_CR4","doi-asserted-by":"publisher","first-page":"11584","DOI":"10.1038\/s41598-018-29917-2","volume":"8","author":"M Kahraman","year":"2018","unstructured":"Kahraman M, R\u00f6ske A, Laufer T et al (2018) MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer. Sci Rep 8:11584. https:\/\/doi.org\/10.1038\/s41598-018-29917-2","journal-title":"Sci Rep"},{"key":"12181_CR5","doi-asserted-by":"publisher","first-page":"e96228","DOI":"10.1371\/journal.pone.0096228","volume":"9","author":"M Ouyang","year":"2014","unstructured":"Ouyang M, Li Y, Ye S et al (2014) MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer. PLoS ONE 9:e96228. https:\/\/doi.org\/10.1371\/journal.pone.0096228","journal-title":"PLoS ONE"},{"key":"12181_CR6","doi-asserted-by":"publisher","first-page":"1134779","DOI":"10.3389\/fgene.2023.1134779","volume":"14","author":"T Singh","year":"2023","unstructured":"Singh T, Kaushik M, Mishra LC et al (2023) Exosomal miRNAs as novel avenues for breast cancer treatment. Front Genet 14:1134779. https:\/\/doi.org\/10.3389\/fgene.2023.1134779","journal-title":"Front Genet"},{"key":"12181_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30179","author":"DP Joyce","year":"2016","unstructured":"Joyce DP, Kerin MJ, Dwyer RM (2016) Exosome-encapsulated microRNAs as circulating biomarkers for breast cancer. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.30179","journal-title":"Int J Cancer"},{"key":"12181_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2147\/BCTT.S432750","volume":"15","author":"J Li","year":"2023","unstructured":"Li J, He D, Bi Y, Liu S (2023) The Emerging Roles of Exosomal miRNAs in Breast Cancer Progression and Potential Clinical Applications. Breast Cancer (Dove Med Press) 15:825\u2013840. https:\/\/doi.org\/10.2147\/BCTT.S432750","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"12181_CR9","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1007\/s00432-022-04189-6","volume":"149","author":"A Mandapati","year":"2023","unstructured":"Mandapati A, Lukong KE (2023) Triple negative breast cancer: approved treatment options and their mechanisms of action. J Cancer Res Clin Oncol 149:3701\u20133719. https:\/\/doi.org\/10.1007\/s00432-022-04189-6","journal-title":"J Cancer Res Clin Oncol"},{"key":"12181_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/antiox10030349","volume":"10","author":"S Mirzaei","year":"2021","unstructured":"Mirzaei S, Zarrabi A, Hashemi F et al (2021) Nrf2 Signaling Pathway in Chemoprotection and Doxorubicin Resistance: Potential Application in Drug Discovery. Antioxid (Basel) 10:349. https:\/\/doi.org\/10.3390\/antiox10030349","journal-title":"Antioxid (Basel)"},{"key":"12181_CR11","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ctrv.2012.02.011","volume":"38","author":"S Murray","year":"2012","unstructured":"Murray S, Briasoulis E, Linardou H et al (2012) Taxane resistance in breast cancer: Mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev 38:890\u2013903. https:\/\/doi.org\/10.1016\/j.ctrv.2012.02.011","journal-title":"Cancer Treat Rev"},{"key":"12181_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.12.009","volume":"527","author":"W Tang","year":"2022","unstructured":"Tang W, Xia M, Liao Y et al (2022) Exosomes in triple negative breast cancer: From bench to bedside. Cancer Lett 527:1\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2021.12.009","journal-title":"Cancer Lett"},{"key":"12181_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3892\/ol.2021.13080","volume":"22","author":"A Sueta","year":"2021","unstructured":"Sueta A, Fujiki Y, Goto-Yamaguchi L et al (2021) Exosomal miRNA profiles of triple-negative breast cancer in neoadjuvant treatment. Oncol Lett 22:819. https:\/\/doi.org\/10.3892\/ol.2021.13080","journal-title":"Oncol Lett"},{"key":"12181_CR14","doi-asserted-by":"publisher","first-page":"e12404","DOI":"10.1002\/jev2.12404","volume":"13","author":"JA Welsh","year":"2024","unstructured":"Welsh JA, Goberdhan DCI, O\u2019Driscoll L et al (2024) Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles 13:e12404. https:\/\/doi.org\/10.1002\/jev2.12404","journal-title":"J Extracell Vesicles"},{"key":"12181_CR15","doi-asserted-by":"publisher","first-page":"20130502","DOI":"10.1098\/rstb.2013.0502","volume":"369","author":"M Li","year":"2014","unstructured":"Li M, Zeringer E, Barta T et al (2014) Analysis of the RNA content of the exosomes derived from blood serum and urine and its potential as biomarkers. Philosophical Trans Royal Soc B: Biol Sci 369:20130502. https:\/\/doi.org\/10.1098\/rstb.2013.0502","journal-title":"Philosophical Trans Royal Soc B: Biol Sci"},{"key":"12181_CR16","doi-asserted-by":"publisher","first-page":"e0170628","DOI":"10.1371\/journal.pone.0170628","volume":"12","author":"I Helwa","year":"2017","unstructured":"Helwa I, Cai J, Drewry MD et al (2017) A Comparative Study of Serum Exosome Isolation Using Differential Ultracentrifugation and Three Commercial Reagents. PLoS ONE 12:e0170628. https:\/\/doi.org\/10.1371\/journal.pone.0170628","journal-title":"PLoS ONE"},{"key":"12181_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12265-016-9682-4","volume":"9","author":"R Kishore","year":"2016","unstructured":"Kishore R, Garikipati VNS, Gumpert A (2016) Tiny Shuttles for Information Transfer: Exosomes in Cardiac Health and Disease. J Cardiovasc Transl Res 9:169\u2013175. https:\/\/doi.org\/10.1007\/s12265-016-9682-4","journal-title":"J Cardiovasc Transl Res"},{"key":"12181_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells12030356","volume":"12","author":"K Stefa\u0144ska","year":"2023","unstructured":"Stefa\u0144ska K, J\u00f3zkowiak M, Angelova Volponi A et al (2023) The role of exosomes in human carcinogenesis and cancer therapy\u2014recent findings from molecular and clinical research. Cells 12:356. https:\/\/doi.org\/10.3390\/cells12030356","journal-title":"Cells"},{"key":"12181_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccr.2014.03.007","volume":"25","author":"W Zhou","year":"2014","unstructured":"Zhou W, Fong MY, Min Y et al (2014) Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 25:501\u2013515. https:\/\/doi.org\/10.1016\/j.ccr.2014.03.007","journal-title":"Cancer Cell"},{"key":"12181_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ncrna5010028","volume":"5","author":"H Schwarzenbach","year":"2019","unstructured":"Schwarzenbach H, Gahan PB (2019) MicroRNA shuttle from cell-to-cell by exosomes and its impact in cancer. Non-Coding RNA 5:28. https:\/\/doi.org\/10.3390\/ncrna5010028","journal-title":"Non-Coding RNA"},{"key":"12181_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091339","volume":"12","author":"J Encarnaci\u00f3n-Medina","year":"2023","unstructured":"Encarnaci\u00f3n-Medina J, Godoy L, Matta J, Ortiz-S\u00e1nchez C (2023) Identification of Exo-miRNAs: a summary of the efforts in translational studies involving triple-negative breast cancer. Cells 12:1339. https:\/\/doi.org\/10.3390\/cells12091339","journal-title":"Cells"},{"key":"12181_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196913","volume":"13","author":"EN Prendergast","year":"2018","unstructured":"Prendergast EN, Fonseca M, Dezem FS et al (2018) Optimizing exosomal RNA isolation for RNA-Seq analyses of archival sera specimens. PLOS ONE 13:e0196913. https:\/\/doi.org\/10.1371\/journal.pone.0196913","journal-title":"PLOS ONE"},{"key":"12181_CR23","doi-asserted-by":"publisher","first-page":"14888","DOI":"10.1073\/pnas.1408301111","volume":"111","author":"JR Chevillet","year":"2014","unstructured":"Chevillet JR, Kang Q, Ruf IK et al (2014) Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci U S A 111:14888\u201314893. https:\/\/doi.org\/10.1073\/pnas.1408301111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12181_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2022.948959","volume":"10","author":"D Xu","year":"2022","unstructured":"Xu D, Di K, Fan B et al (2022) MicroRNAs in extracellular vesicles: sorting mechanisms, diagnostic value, isolation, and detection technology. Frontiers in Bioengineering and Biotechnology 10:948959. https:\/\/doi.org\/10.3389\/fbioe.2022.948959","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"12181_CR25","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1158\/0008-5472.CAN-16-0359","volume":"76","author":"AA Svoronos","year":"2016","unstructured":"Svoronos AA, Engelman DM, Slack FJ (2016) OncomiR or tumor suppressor? The duplicity of microRNAs in cancer. Cancer Res 76:3666\u20133670. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0359","journal-title":"Cancer Res"},{"key":"12181_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00472","volume":"10","author":"Q Guo","year":"2020","unstructured":"Guo Q, Wang H, Yan Y et al (2020) The role of exosomal microRNA in cancer drug resistance. Front Oncol 10:472. https:\/\/doi.org\/10.3389\/fonc.2020.00472","journal-title":"Front Oncol"},{"key":"12181_CR27","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/iub.2116","volume":"71","author":"H Najminejad","year":"2019","unstructured":"Najminejad H, Kalantar SM, Abdollahpour-Alitappeh M et al (2019) Emerging roles of exosomal miRNAs in breast cancer drug resistance. IUBMB Life 71:1672\u20131684. https:\/\/doi.org\/10.1002\/iub.2116","journal-title":"IUBMB Life"},{"key":"12181_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2022.03.004","volume":"25","author":"X Huang","year":"2022","unstructured":"Huang X, Lai S, Qu F et al (2022) CCL18 promotes breast cancer progression by exosomal miR-760 activation of ARF6\/Src\/PI3K\/Akt pathway. Mol Ther Oncolytics 25:1\u201315. https:\/\/doi.org\/10.1016\/j.omto.2022.03.004","journal-title":"Mol Ther Oncolytics"},{"key":"12181_CR29","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12967-024-05947-5","volume":"23","author":"M Wang","year":"2025","unstructured":"Wang M, Zheng Y, Hao Q et al (2025) Hypoxic BMSC-derived exosomal miR-210-3p promotes progression of triple-negative breast cancer cells via NFIX-Wnt\/\u03b2-catenin signaling axis. J Translational Med 23:39. https:\/\/doi.org\/10.1186\/s12967-024-05947-5","journal-title":"J Translational Med"},{"key":"12181_CR30","doi-asserted-by":"publisher","first-page":"5874","DOI":"10.3390\/cancers13235874","volume":"13","author":"I Cavallari","year":"2021","unstructured":"Cavallari I, Ciccarese F, Sharova E et al (2021) The miR-200 Family of microRNAs: Fine Tuners of Epithelial-Mesenchymal Transition and Circulating Cancer Biomarkers. Cancers (Basel) 13:5874. https:\/\/doi.org\/10.3390\/cancers13235874","journal-title":"Cancers (Basel)"},{"key":"12181_CR31","doi-asserted-by":"publisher","first-page":"5109","DOI":"10.1172\/JCI75695","volume":"124","author":"MTN Le","year":"2014","unstructured":"Le MTN, Hamar P, Guo C et al (2014) miR-200\u2013containing extracellular vesicles promote breast cancer cell metastasis. J Clin Invest 124:5109\u20135128. https:\/\/doi.org\/10.1172\/JCI75695","journal-title":"J Clin Invest"},{"key":"12181_CR32","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/1354750X.2024.2406520","volume":"29","author":"P Qiao","year":"2024","unstructured":"Qiao P, Du H, Guo X et al (2024) Serum exosomal miR-200c is a potential diagnostic biomarker for breast cancer. Biomarkers 29:419\u2013426. https:\/\/doi.org\/10.1080\/1354750X.2024.2406520","journal-title":"Biomarkers"},{"key":"12181_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3892\/mmr.2014.2222","volume":"10","author":"Y Ren","year":"2014","unstructured":"Ren Y, Han X, Yu K et al (2014) microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells. Mol Med Rep 10:315\u2013321. https:\/\/doi.org\/10.3892\/mmr.2014.2222","journal-title":"Mol Med Rep"},{"key":"12181_CR34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41523-021-00273-1","volume":"7","author":"MM Williams","year":"2021","unstructured":"Williams MM, Christenson JL, O\u2019Neill KI et al (2021) MicroRNA-200c restoration reveals a cytokine profile to enhance M1 macrophage polarization in breast cancer. npj Breast Cancer 7:64. https:\/\/doi.org\/10.1038\/s41523-021-00273-1","journal-title":"npj Breast Cancer"},{"key":"12181_CR35","doi-asserted-by":"publisher","first-page":"10253","DOI":"10.18632\/oncotarget.3520","volume":"6","author":"N Bovy","year":"2015","unstructured":"Bovy N, Blomme B, Fr\u00e8res P et al (2015) Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget 6:10253\u201310266. https:\/\/doi.org\/10.18632\/oncotarget.3520","journal-title":"Oncotarget"},{"key":"12181_CR36","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.omto.2020.10.008","volume":"19","author":"T Luo","year":"2020","unstructured":"Luo T, Liu Q, Tan A et al (2020) Mesenchymal Stem Cell-Secreted Exosome Promotes Chemoresistance in Breast Cancer via Enhancing miR-21-5p-Mediated S100A6 Expression. Mol Ther Oncolytics 19:283\u2013293. https:\/\/doi.org\/10.1016\/j.omto.2020.10.008","journal-title":"Mol Ther Oncolytics"},{"key":"12181_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-19339-5","volume":"8","author":"JC Santos","year":"2018","unstructured":"Santos JC, Lima N, Sarian LO et al (2018) Exosome-mediated breast cancer chemoresistance via miR-155 transfer. Sci Rep 8:829. https:\/\/doi.org\/10.1038\/s41598-018-19339-5","journal-title":"Sci Rep"},{"key":"12181_CR38","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1073\/pnas.1402604111","volume":"111","author":"P Gasparini","year":"2014","unstructured":"Gasparini P, Lovat F, Fassan M et al (2014) Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. Proc Natl Acad Sci U S A 111:4536\u20134541. https:\/\/doi.org\/10.1073\/pnas.1402604111","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12181_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biom16050682","volume":"16","author":"J Chung","year":"2026","unstructured":"Chung J, Soung YH (2026) Exosomal MicroRNAs as Drivers of Desmoplasia and Treatment Resistance in Breast Cancer: Mechanisms, Biomarker Potential, and Therapeutic Opportunities. Biomolecules 16:682. https:\/\/doi.org\/10.3390\/biom16050682","journal-title":"Biomolecules"},{"key":"12181_CR40","doi-asserted-by":"publisher","first-page":"7880","DOI":"10.2174\/0109298673341499241016110341","volume":"32","author":"J Razaviyan","year":"2025","unstructured":"Razaviyan J, Sirati-Sabet M, Hadavi R et al (2025) Exosomal Delivery of miR-155 Inhibitor can Suppress Migration, Invasion, and Angiogenesis Via PTEN and DUSP14 in Triple-negative Breast Cancer. Curr Med Chem 32:7880\u20137893. https:\/\/doi.org\/10.2174\/0109298673341499241016110341","journal-title":"Curr Med Chem"},{"key":"12181_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/biom15050685","volume":"15","author":"G Liu","year":"2025","unstructured":"Liu G, Liu J, Li S et al (2025) Exosome-Mediated Chemoresistance in Cancers: Mechanisms, Therapeutic Implications, and Future Directions. Biomolecules 15:685. https:\/\/doi.org\/10.3390\/biom15050685","journal-title":"Biomolecules"},{"key":"12181_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23105324","volume":"23","author":"S Joshi","year":"2022","unstructured":"Joshi S, Garlapati C, Bhattarai S et al (2022) Exosomal Metabolic Signatures Are Associated with Differential Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer. Int J Mol Sci 23:5324. https:\/\/doi.org\/10.3390\/ijms23105324","journal-title":"Int J Mol Sci"},{"key":"12181_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.breast.2016.08.014","volume":"30","author":"X Huang","year":"2016","unstructured":"Huang X, Li X, Xie X et al (2016) High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. The Breast 30:39\u201346. https:\/\/doi.org\/10.1016\/j.breast.2016.08.014","journal-title":"The Breast"},{"key":"12181_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00428","volume":"10","author":"X Sun","year":"2020","unstructured":"Sun X, Wang M, Wang M et al (2020) Metabolic reprogramming in triple-negative breast cancer. Frontiers in Oncology 10:428. https:\/\/doi.org\/10.3389\/fonc.2020.00428","journal-title":"Frontiers in Oncology"},{"key":"12181_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102411","volume":"15","author":"M Vlasiou","year":"2023","unstructured":"Vlasiou M, Nicolaidou V, Papaneophytou C (2023) Targeting lactate dehydrogenase-B as a strategy to fight cancer: identification of potential inhibitors by in silico analysis and in vitro screening. Pharmaceutics 15:2411. https:\/\/doi.org\/10.3390\/pharmaceutics15102411","journal-title":"Pharmaceutics"},{"key":"12181_CR46","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201600370","volume":"17","author":"L Gangoda","year":"2017","unstructured":"Gangoda L, Liem M, Ang C et al (2017) Proteomic profiling of exosomes secreted by breast cancer cells with varying metastatic potential. Proteomics 17:1600370. https:\/\/doi.org\/10.1002\/pmic.201600370","journal-title":"Proteomics"},{"key":"12181_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-02952-6","volume":"11","author":"Y Du","year":"2020","unstructured":"Du Y, Wei N, Ma R et al (2020) A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1\u03b1 and p53 activity in triple-negative breast cancer. Cell Death Dis 11:731. https:\/\/doi.org\/10.1038\/s41419-020-02952-6","journal-title":"Cell Death Dis"},{"key":"12181_CR48","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/ncb3094","volume":"17","author":"MY Fong","year":"2015","unstructured":"Fong MY, Zhou W, Liu L et al (2015) Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol 17:183\u2013194. https:\/\/doi.org\/10.1038\/ncb3094","journal-title":"Nat Cell Biol"},{"key":"12181_CR49","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41556-018-0083-6","volume":"20","author":"W Yan","year":"2018","unstructured":"Yan W, Wu X, Zhou W et al (2018) Cancer-cell-secreted exosomal miR-105 promotes tumour growth through the MYC-dependent metabolic reprogramming of stromal cells. Nat Cell Biol 20:597\u2013609. https:\/\/doi.org\/10.1038\/s41556-018-0083-6","journal-title":"Nat Cell Biol"},{"key":"12181_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygeno.2022.110341","volume":"114","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lai X, Yue Q et al (2022) Bone marrow mesenchymal stem cells-derived exosomal microRNA-16-5p restrains epithelial-mesenchymal transition in breast cancer cells via EPHA1\/NF-\u03baB signaling axis. Genomics 114:110341. https:\/\/doi.org\/10.1016\/j.ygeno.2022.110341","journal-title":"Genomics"},{"key":"12181_CR51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.18632\/aging.202148","volume":"13","author":"L Xing","year":"2020","unstructured":"Xing L, Tang X, Wu K et al (2020) LncRNA HAND2-AS1 suppressed the growth of triple negative breast cancer via reducing secretion of MSCs derived exosomal miR-106a-5p. Aging (Albany NY) 13:424\u2013436. https:\/\/doi.org\/10.18632\/aging.202148","journal-title":"Aging (Albany NY)"},{"key":"12181_CR52","doi-asserted-by":"publisher","first-page":"5832","DOI":"10.1158\/0008-5472.CAN-16-1092","volume":"76","author":"SA Bliss","year":"2016","unstructured":"Bliss SA, Sinha G, Sandiford OA et al (2016) Mesenchymal Stem Cell\u2013Derived Exosomes Stimulate Cycling Quiescence and Early Breast Cancer Dormancy in Bone Marrow. Cancer Res 76:5832\u20135844. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-1092","journal-title":"Cancer Res"},{"issue":"332","key":"12181_CR53","doi-asserted-by":"publisher","first-page":"ra63","DOI":"10.1126\/scisignal.2005231","volume":"7","author":"M Ono","year":"2014","unstructured":"Ono M, Kosaka N, Tominaga N et al (2014) Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal 7:ra63. https:\/\/doi.org\/10.1126\/scisignal.2005231","journal-title":"Sci Signal"},{"key":"12181_CR54","doi-asserted-by":"publisher","first-page":"e2312","DOI":"10.1038\/cddis.2016.224","volume":"7","author":"S Baroni","year":"2016","unstructured":"Baroni S, Romero-Cordoba S, Plantamura I et al (2016) Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts. Cell Death Dis 7:e2312\u2013e2312. https:\/\/doi.org\/10.1038\/cddis.2016.224","journal-title":"Cell Death Dis"},{"key":"12181_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092143","volume":"9","author":"G Cosentino","year":"2020","unstructured":"Cosentino G, Romero-Cordoba S, Plantamura I et al (2020) miR-9-Mediated Inhibition of EFEMP1 Contributes to the Acquisition of Pro-Tumoral Properties in Normal Fibroblasts. Cells 9:2143. https:\/\/doi.org\/10.3390\/cells9092143","journal-title":"Cells"},{"key":"12181_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1204224","author":"R Graham","year":"2023","unstructured":"Graham R, Gazinska P, Zhang B et al (2023) Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1204224","journal-title":"Front Immunol"},{"key":"12181_CR57","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.cell.2014.09.051","volume":"159","author":"MC Boelens","year":"2014","unstructured":"Boelens MC, Wu TJ, Nabet BY et al (2014) Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways. Cell 159:499\u2013513. https:\/\/doi.org\/10.1016\/j.cell.2014.09.051","journal-title":"Cell"},{"key":"12181_CR58","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1039\/d0nr00523a","volume":"12","author":"S Li","year":"2020","unstructured":"Li S, Wu Y, Ding F et al (2020) Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale 12:10854\u201310862. https:\/\/doi.org\/10.1039\/d0nr00523a","journal-title":"Nanoscale"},{"key":"12181_CR59","doi-asserted-by":"publisher","first-page":"804","DOI":"10.2174\/1389200220666190819151946","volume":"20","author":"B Wang","year":"2019","unstructured":"Wang B, Zhang Y, Ye M et al (2019) Cisplatin-resistant MDA-MB-231 Cell-derived Exosomes Increase the Resistance of Recipient Cells in an Exosomal miR-423-5p-dependent Manner. Curr Drug Metab 20:804\u2013814. https:\/\/doi.org\/10.2174\/1389200220666190819151946","journal-title":"Curr Drug Metab"},{"key":"12181_CR60","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1089\/cbr.2023.0123","volume":"39","author":"X Hong","year":"2024","unstructured":"Hong X, Pan X (2024) Exosome-Derived MicroRNA-221-3p Desensitizes Breast Cancer Cells to Adriamycin by Regulating PIK3r1-Mediated Glycose Metabolism. Cancer Biother Radiopharm 39:463\u2013475. https:\/\/doi.org\/10.1089\/cbr.2023.0123","journal-title":"Cancer Biother Radiopharm"},{"key":"12181_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-017-0030-7","volume":"9","author":"Y Li","year":"2018","unstructured":"Li Y, Liang Y, Sang Y et al (2018) MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. Cell Death Dis 9:1\u201312. https:\/\/doi.org\/10.1038\/s41419-017-0030-7","journal-title":"Cell Death Dis"},{"key":"12181_CR62","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.yexcr.2018.05.014","volume":"369","author":"J Ding","year":"2018","unstructured":"Ding J, Xu Z, Zhang Y et al (2018) Exosome-mediated miR-222 transferring: An insight into NF-\u03baB-mediated breast cancer metastasis. Exp Cell Res 369:129\u2013138. https:\/\/doi.org\/10.1016\/j.yexcr.2018.05.014","journal-title":"Exp Cell Res"},{"issue":"1","key":"12181_CR63","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s11658-022-00393-x","volume":"27","author":"Z Liang","year":"2022","unstructured":"Liang Z, Liu L, Gao R et al (2022) Downregulation of exosomal miR-7-5p promotes breast cancer migration and invasion by targeting RYK and participating in the atypical WNT signalling pathway. Cell Mol Biol Lett 27:88. https:\/\/doi.org\/10.1186\/s11658-022-00393-x","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"12181_CR64","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13058-017-0918-2","volume":"19","author":"H-Y Li","year":"2017","unstructured":"Li H-Y, Liang J-L, Kuo Y-L et al (2017) miR-105\/93-3p promotes chemoresistance and circulating miR-105\/93-3p acts as a diagnostic biomarker for triple negative breast cancer. Breast Cancer Res 19:133. https:\/\/doi.org\/10.1186\/s13058-017-0918-2","journal-title":"Breast Cancer Res"},{"key":"12181_CR65","doi-asserted-by":"publisher","first-page":"8733","DOI":"10.2147\/CMAR.S270200","volume":"12","author":"Z Jia","year":"2020","unstructured":"Jia Z, Zhu H, Sun H et al (2020) Adipose Mesenchymal Stem Cell-Derived Exosomal microRNA-1236 Reduces Resistance of Breast Cancer Cells to Cisplatin by Suppressing SLC9A1 and the Wnt\/\u03b2-Catenin Signaling. Cancer Manag Res 12:8733\u20138744. https:\/\/doi.org\/10.2147\/CMAR.S270200","journal-title":"Cancer Manag Res"},{"issue":"1","key":"12181_CR66","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12951-019-0526-7","volume":"17","author":"C Gong","year":"2019","unstructured":"Gong C, Tian J, Wang Z et al (2019) Functional exosome-mediated co-delivery of doxorubicin and hydrophobically modified microRNA 159 for triple-negative breast cancer therapy. J Nanobiotechnol 17:93. https:\/\/doi.org\/10.1186\/s12951-019-0526-7","journal-title":"J Nanobiotechnol"},{"issue":"1","key":"12181_CR67","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12885-025-15499-6","volume":"26","author":"A Choudhary","year":"2026","unstructured":"Choudhary A, Poojary SS, Jain P et al (2026) Identification of novel exosomal miRNAs and their role in diagnosis and prognosis of triple negative breast cancer. BMC Cancer 26:210. https:\/\/doi.org\/10.1186\/s12885-025-15499-6","journal-title":"BMC Cancer"},{"key":"12181_CR68","doi-asserted-by":"publisher","first-page":"e38549","DOI":"10.1097\/MD.0000000000038549","volume":"103","author":"L Yang","year":"2024","unstructured":"Yang L, Fan J, Dong C et al (2024) Correlative expression of exosomal miRNAs in chemotherapy resistance of triple-negative breast cancer: An observational study. Med (Baltim) 103:e38549. https:\/\/doi.org\/10.1097\/MD.0000000000038549","journal-title":"Med (Baltim)"},{"key":"12181_CR69","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.3390\/molecules28041802","volume":"28","author":"M Banerjee","year":"2023","unstructured":"Banerjee M, Rajeswari VD (2023) Critical Review on the Different Roles of Exosomes in TNBC and Exosomal-Mediated Delivery of microRNA\/siRNA\/lncRNA and Drug Targeting Signalling Pathways in Triple-Negative Breast Cancer. Molecules 28:1802. https:\/\/doi.org\/10.3390\/molecules28041802","journal-title":"Molecules"},{"key":"12181_CR70","doi-asserted-by":"publisher","first-page":"32774","DOI":"10.18632\/oncotarget.5192","volume":"6","author":"K O\u2019Brien","year":"2015","unstructured":"O\u2019Brien K, Lowry MC, Corcoran C et al (2015) miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 6:32774\u201332789. https:\/\/doi.org\/10.18632\/oncotarget.5192","journal-title":"Oncotarget"},{"key":"12181_CR71","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s13046-021-01901-1","volume":"40","author":"Q Yang","year":"2021","unstructured":"Yang Q, Zhao S, Shi Z et al (2021) Chemotherapy-elicited exosomal miR-378a-3p and miR-378d promote breast cancer stemness and chemoresistance via the activation of EZH2\/STAT3 signaling. J Experimental Clin Cancer Res 40:120. https:\/\/doi.org\/10.1186\/s13046-021-01901-1","journal-title":"J Experimental Clin Cancer Res"},{"key":"12181_CR72","doi-asserted-by":"publisher","first-page":"11502","DOI":"10.3390\/ijms231911502","volume":"23","author":"A Menon","year":"2022","unstructured":"Menon A, Abd-Aziz N, Khalid K et al (2022) miRNA: A Promising Therapeutic Target in Cancer. Int J Mol Sci 23:11502. https:\/\/doi.org\/10.3390\/ijms231911502","journal-title":"Int J Mol Sci"},{"key":"12181_CR73","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1007\/s12015-020-10089-4","volume":"17","author":"S Shojaei","year":"2021","unstructured":"Shojaei S, Hashemi SM, Ghanbarian H et al (2021) Delivery of miR-381-3p Mimic by Mesenchymal Stem Cell-Derived Exosomes Inhibits Triple Negative Breast Cancer Aggressiveness; an In Vitro Study. Stem Cell Rev Rep 17:1027\u20131038. https:\/\/doi.org\/10.1007\/s12015-020-10089-4","journal-title":"Stem Cell Rev Rep"},{"key":"12181_CR74","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/ijms25042070","volume":"25","author":"S Fahmy","year":"2024","unstructured":"Fahmy S, Mahdy N, Mohamed A et al (2024) Hijacking 5-Fluorouracil Chemoresistance in Triple Negative Breast Cancer via microRNAs-Loaded Chitosan Nanoparticles. Int J Mol Sci 25:2070. https:\/\/doi.org\/10.3390\/ijms25042070","journal-title":"Int J Mol Sci"},{"key":"12181_CR75","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/mt.2012.180","volume":"21","author":"S Ohno","year":"2013","unstructured":"Ohno S, Takanashi M, Sudo K et al (2013) Systemically Injected Exosomes Targeted to EGFR Deliver Antitumor MicroRNA to Breast Cancer Cells. Mol Ther 21:185\u2013191. https:\/\/doi.org\/10.1038\/mt.2012.180","journal-title":"Mol Ther"},{"key":"12181_CR76","doi-asserted-by":"publisher","first-page":"126147","DOI":"10.1016\/j.ijbiomac.2023.126147","volume":"250","author":"X Liu","year":"2023","unstructured":"Liu X, Zhang G, Yu T et al (2023) CL4-modified exosomes deliver lncRNA DARS-AS1 siRNA to suppress triple-negative breast cancer progression and attenuate doxorubicin resistance by inhibiting autophagy. Int J Biol Macromol 250:126147. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.126147","journal-title":"Int J Biol Macromol"},{"key":"12181_CR77","doi-asserted-by":"publisher","first-page":"e70785","DOI":"10.1002\/cam4.70785","volume":"14","author":"J He","year":"2025","unstructured":"He J, He F, Yang Q, Li Q (2025) Blockade of Exosome Release Sensitizes Breast Cancer to Doxorubicin via Inhibiting Angiogenesis. Cancer Med 14:e70785. https:\/\/doi.org\/10.1002\/cam4.70785","journal-title":"Cancer Med"},{"key":"12181_CR78","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/app14041639","volume":"14","author":"E Serretiello","year":"2024","unstructured":"Serretiello E, Smimmo A, Ballini A et al (2024) Extracellular Vesicles and Artificial Intelligence: Unique Weapons against Breast Cancer. Appl Sci 14:1639. https:\/\/doi.org\/10.3390\/app14041639","journal-title":"Appl Sci"},{"key":"12181_CR79","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12916-018-1163-y","volume":"16","author":"I Stevic","year":"2018","unstructured":"Stevic I, M\u00fcller V, Weber K et al (2018) Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Med 16:179. https:\/\/doi.org\/10.1186\/s12916-018-1163-y","journal-title":"BMC Med"},{"key":"12181_CR80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ncrna9020027","volume":"9","author":"E Bayraktar","year":"2023","unstructured":"Bayraktar E, Bayraktar R, Oztatlici H et al (2023) Targeting miRNAs and Other Non-Coding RNAs as a Therapeutic Approach: An Update. Noncoding RNA 9:27. https:\/\/doi.org\/10.3390\/ncrna9020027","journal-title":"Noncoding RNA"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12181-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12181-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:29:15Z","timestamp":1782217755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12181-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12181"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12181-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"15 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no known conflicts of interest or competing financial interests that are directly or indirectly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"983"}}